Zydus Brochure - Single

NURTURING LIFE
www.zyduscadila.com

State-of-the-art
formulations manufacturing
hub and QA/QC facility at
Moraiya, Ahmedabad

MISSION
We are dedicated to life… in all its dimensions.
Our world is shaped by a passion for innovation,
commitment to partners and concern for people
in an effort to create healthier communities, globally.
VISION
Zydus shall be a leading global healthcare provider
with a robust product pipeline;
Opening up new pathways through innovation and
quality excellence, we shall be a research-based
company by 2020.

IN A NUTSHELL
CORPORATE FACT SHEET
Life is a beautiful gift. Across the world,
communities celebrate this fundamental truth in
various ways. We, at Zydus, are committed to
nurturing life by contributing to the health and
wellbeing of humanity across the globe. In our
journey spanning more than six decades, we have
been touching lives and making a difference in a
myriad ways as we live our mission of creating
healthier, happier communities globally.
HISTORY
Established in 1952 as Cadila Laboratories and
founded by late Mr. Ramanbhai B. Patel, the group
grew to become the second largest
pharmaceutical company in the early 1990s. In
1995, the group restructured its operations and
emerged as a new identity under the aegis of the
Zydus Group as Cadila Healthcare Ltd.
GEOGRAPHIC REACH
With the vision of nurturing life across the world,
Zydus reached out to other parts of the world and
extended its operations through subsidiaries in
the US, Europe (France and Spain) and high profile
markets in Latin America and South America.
Besides, it expanded its global presence in 25
other emerging markets around the world.
GROWTH RECORD (1995 - 2017)
From a turnover of ` 200 crores in 1995, the
group entered the billion-dollar league in 2011.
The group registered a turnover of over ` 11600
crores in 2017-18.
The group was ranked 4 th in the domestic pharma
market as compared to the 16 th rank in 1995.
From being a domestic formulations-focussed
business, today the group is a global, integrated
company with major strengths all across the
pharmaceutical value chain.

FACTS AT A GLANCE
65+
years of
operational
experience
9 th largest
Generic Co.
in US in terms
of prescriptions
The 1 st Indian
pharma company
to discover & develop an
NCE in-house : Lipaglyn
(Saroglitazar)
$ 1.80+ bn
Global Revenues
Among top 5
Pharmaceutical
Companies in
India
1 st Company
to launch
biosimilar
of Adalimumab
anywhere in the
world
~24% CAGR in
Net Worth
(FY ‘16 – FY ‘18)
16 brands
among
top 300 brands
in India
21 Biosimilars
(pipeline & launched)
& 6 novel products
(pipeline)
$ 6.2 bn
Market Cap
21,000+
employees across
the globe with more
than1400 for R&D
400+ patents
granted
worldwide
33 mfg. sites
producing more than
28 bn pills annually
8 R&D Centers
for NCE, APIs,
Generic formulations,
Biosimilars and
Vaccines

THE ZYDUS JOURNEY
REALIZING A DREAM
A man with a vision:
Born at Kathor in South Gujarat on 19th August, 1925,
Mr. Ramanbhai B. Patel was a man with intense vision and
clear foresight. Beginning his career as an academician at
the LM College of Pharmacy, Ahmedabad, Gujarat, he
became a pharma entrepreneur in 1952 after a short stint
in academics. Little did he know that this decision would
change the pharmaceutical landscape of the world
forever. His sound business acumen helped him lay the
foundation for Cadila, thereby contributing to the strong
growth of the Indian pharmaceutical industry. Today,
Zydus Cadila is one of the largest pharma groups in the
country; nurturing the pharma landscape with care,
responsibility, and consideration. The company grew
rapidly under his leadership.
An Unparalleled Academician:
“For my part, I had a dream to
contribute to the process of nation
building and of becoming a successful
entrepreneur.
Over the years, I put my heart and soul
into realizing this dream and was also
fortunate to have people join me and
share this vision.
I am happy to have been able to give a
concrete shape to my dreams and build
the edifice of an enterprise which I am
sure will continue to transform itself in
response to the changing times.”
Shri Ramanbhai B. Patel
Late Founder Chairman, Zydus Cadila
(August 19, 1925 - September 19, 2001)
Mr. Ramanbhai B. Patel’s parallel interest in academics led
him to publish several outstanding research papers. He
was also actively involved in several research activities
within the group. It is due to his genuine interest and
dedication to research that Zydus Cadila is amongst the
top-notch investors in research today.
Mr. Ramanabhai B. Patel was a noteworthy contributor to
pharmaceutical education and was instrumental in taking
pharmaceutical education to the rural heartland of
Gujarat and making professional courses more accessible
to students in smaller townships. Take for example the
state of Gujarat, which had only one Pharmacy College
previously, but now boasts of ten reputed pharmacy
colleges.
Rewards and recognition:
In recognition of his services, Mr. Ramanbhai B. Patel was
bestowed upon with several prestigious awards. Some of
these awards are:
• President of India’s Import Substitution Award 1973
• Prof. M.L. Shroff Memorial National Award 1987
• The Glory of India Award 1991 at Washington
• Grahak Suraksha Award 1992
• Acharya Prafulla Chandra Ray Memorial Gold Medal 1993
• Eminent Pharmacist Award 1994
Humble beginnings:
At the time of India’s independence, the total value of
allopathic drugs and formulations produced in the
country amounted to ` 10 crores per year. Moreover, the
production scene was dominated by multinationals. It had
become crucial to prove that an indigenous company
could come out with innovative and research-based
quality products. Cadila had already achieved the
distinction of being one of the oldest pharmaceutical
companies in India. Moreover, Cadila was one of the first

Indian companies, which was able to break the
stranglehold of multinationals over the Indian market.
From a humble beginning of establishing a plant in a
three-room house located at Azad Society, close to
Gandhidham Station in Gujarat, to becoming the Second
Largest Pharmaceutical Company in India, Cadila has set
benchmark for excellence and success.
Moving ahead:
With the infrastructure established by Mr. Ramanbhai B.
Patel in place the company began working on its first
product- Livirubra.
Around that time, a new molecule vitamin B12 had been
introduced to combat pernicious anaemia. The new
product Livirubra was a combination of intrinsic factors,
lipotripic factors, iron, folic acid, and vitamin B12. Actually,
the lack of intrinsic factor, which is produced by the
stomach lining, causes impaired uptake of vitamin B12.
Further, too little vitamin B12 in the body causes
pernicious anaemia. The combination of the intrinsic
factor and vitamin B12 remained only a hypothesis until it
was first applied in Livirubra. Cadila’s very first product
was innovative and it set the trend of new product
innovations that were to follow in the years to come.
Definin and driin innoation
After the initial success of Livirubra, Cadila introduced a
new product called Isopar, which was a derivative of INH
(an antibiotic used for the treatment of tuberculosis). This
drug was the first to be launched in the market in this part
of the world. Moreover, Cadila also manufactured the raw
material for the drug indigenously. It turned out to be one
of the star brands with sales of more than 60 lakh tablets
per year in those days.
Successive new product introductions and superior
brand management skills scripted much of Cadila’s
success. By the early 1990’s, Cadila rose to become the
second largest pharmaceutical company in India. The
success of Cadila can be attributed to the founder’s vision
and the resoluteness of the employees to script the
success story that Cadila is today.
In 1995, faced with a changing business environment, the
group decided to restructure its operations. The ensuing
restructuring saw the birth of Cadila Healthcare, under
the aegis of the newly formed Zydus Group, with a focus
on total healthcare solutions.

THE ZYDUS GROUP
EMPOWERING GROWTH IN FOUR CONTINENTS
Zydus has strong commercial footprints in four key markets (India, US, Brazil/
Mexico & EU - France & Spain). More than 2/3rds of the $1 billion in sales is
generated from these four major markets.
Nesher Pharmaceuticals
at St. Louis, Missouri,
USA.
Zydus Pharmaceuticals
(USA) Inc
HQ : Princeton, NJ
Recently made a foray in
the specialty prescription
market with the acquisition
of San Diego based
Sentynl Therapeutics
Zydus France SAS
HQ : Paris
Laboratorios
Combix Spain
HQ : Madrid
Zydus in
the European
Union
USA
Mexico
EU
AFRICA
Middle
East
ASIA
HQ : Ahmedabad
Zydus Pharmaceuticals
Mexico S.A. de C.V.
HQ : Mexico City
LATAM
Zydus Healthcare SA PTY Ltd.
HQ : Pretoria, South Africa
Zydus Nikkho
Pharmaceutica Ltda, Brazil
HQ : Rio de Janeiro
Emerging Markets Business
(Latin America, Africa,
Midde ast, Asia acific,
Mexico

AT THE HELM
At the helm of affairs at Zydus are some of the
topmost professionals in the pharmaceutical field.
Having honed their acumen in the nitty-gritty of
the business, they now lead Zydus towards newer
horizons and further dimensions of growth and
success.
Mr. Pankaj R. Patel
Chairman
Dr. Sharvil P. Patel
Managing Director
Mr. Ganesh Nayak
COO and Executive Director
LEADERSHIP TEAM
Dr. Amrut Naik
President and Head,
Emerging Markets
Business
Mr. Anil Matai
Managing Director,
Zydus Healthcare Ltd
Dr. Arun Atrey
President & Head,
Global Animal Health
Business
Mr. Gaurav Suchak
Vice President & Head,
GDSO
Mr. Harish Sadana
Chief trategy cer
Mr. Marc Kikuchi
CEO Americas, USA
Mr. M. E. Kannan
Head, Pharmaceutical
Technology Centre
Mr. Nitin Parekh
Chief inancial cer
Mr. Prashant Sharma
President - Formulations
Manufacturing Operations
Mr. Rishikesh Raval
Sr. Vice President,
Human Resources
Mr. Samir Desai
President, SBU Biologics
Mr. Tarun Arora
Chief Operating cer
Zydus Wellness
Mr. Udayan Ambegaokar
President, API
Mr. Vipul Doshi
President, Global Quality
Assurance & IRA

VERTICALLY INTEGRATED OPERATIONS
ACROSS THE VALUE CHAIN
RESEARCH AND
DEVELOPMENT
INTERNATIONAL
FINISHED DOSAGE
FORMULATIONS
OUR CORE
BUSINESSES
HIGH END APIs +
INTERMEDIATES
MANUFACTURING
INDIAN FINISHED
DOSAGE
FORMULATIONS
ANIMAL
HEALTH
WELLNESS

FOSTERING INNOVATION FOR
BETTER HEALTHCARE SOLUTIONS
More than 1200 researchers spearhead our
Innovation programme across 19 sites, working
on differentiated medicines, which cover a
broad spectrum from NCEs (New Chemical
Entities) to vaccines, bio-similars and niche
technologies.
NCE RESEARCH
• Cardio-Metabolic diseases
Inammation pain
• Oncology
BIOLOGICS
• Biosimilar Therapeutic proteins
• Biosimilar Monoclonal antibodies
• Biobetters and Novel biologics
VACCINES
• Infectious diseases

BRIDGING UNMET HEALTHCARE NEEDS
THROUGH INDIGENOUS INNOVATION
Zypitamag marks the first-ever branded product launch
for our group in the US. This 505 (b) (2) new drug
application product – pitavastatin magnesium - is used
to manage cholesterol levels and is approved in the
strengths of 1 mg, 2 mg and 4 mg. Medicure
International Inc. markets the drug for our group in the
US .
The world’s first biosimilar of
Adalimumab – the largest selling
therapy globally for treating autoimmune
disorders is now
available for the first time ever in
India.
Bringing India’s Innovation
success to the forefront once
again - researched, developed
and produced by scientists at the
Zydus Research Centre, Exemptia
is a fingerprint match with the
originator in terms of safety,
purity and potency of the
product.
For more than a decade, patients
in India suffering from
auto-immune disorders like
rheumatoid arthritis, ankylosing
spondylitis, psoriatic arthritis and
juvenile idiopathic arthritis did not
have access to Adalimumab - a
revolutionary therapy.
Nearly 12 million patients in India
suffer from these chronic conditions,
which progressively deteriorate and
lead to lifelong pain and in some
cases, even disability.
Exemptia Adalimumab provides a new
lease of life to Indian patients of
inammatory arthritis, who did not
have access to this revolutionary
therapy, so far.

aiu ndias st Tetraaent nactiated nuena accine
It provides protection from the four inuena viruses H1N1, HN2, Type B (Brisbane) and
Type B (Phuket) viruses. Today, Zydus is only the second company in the world to launch a
tetravalent inactivated inuena vaccine.
This vaccine has been developed at the
Vaccine Technology Centre (VTC) in
Ahmedabad, which has proven
capabilities in researching, developing,
and manufacturing of safe and
ecacious vaccines. Zydus axxicare a
division of the Zydus group that focuses
on preventives markets axiu 4 in
potential target markets across the
country.
Launched Lipaglyn in September 2013
This is a novel drug to treat diabetic
dyslipidemia – a global, unmet healthcare need.
It is also the 1 st NCE from an Indian research
pipeline to move from the lab to the market.
Lipaglyn offers dual benefits of lipid and
glycemic control in one single molecule. Zydus
led an innovation yet again that helped over
500,000 people suffering from diabetic
dyslipidemia in India lead healthier lives.

API RESEARCH
NCEs
MONOCLONAL ANTIBODIES
NUTRACEUTICALS
FORMULATION DEVELOPMENT
BIOLOGICALS
SMALL MOLECULES
PEPTIDES
CONTROLLED SUBSTANCES
WELLNESS PRODUCTS
Spread over an area of over 4,75,000 sq ft, the Zydus
Research Centre (ZRC) works on cutting- edge technologies
in dierent scientific disciplines to discover novel
therapeutic agents. The centre has capabilities to conduct
drug discovery & development from concept to
Investigational New Drugs (IND) enabling preclinical and
clinical studies. With its team of over 450 research
professionals, ZRC spearheads the group’s quest of creating
healthier and happier communities globally.

SETTING GLOBAL FOOTPRINTS WITH
A STATE-OF-THE ART MANUFACTURING INFRASTRUCTURE
• Manufacturing capabilities across the value chain - formulations, APIs, vaccines, biosimilars, complex
products (transdermals, topical etc.), animal health products as well as wellness products
• 30+ manufacturing plants worldwide including India, Germany, Brazil & USA
Finished Dosage Form, Baddi Finished Dosage Form, Goa Fomulations plant at Sikkim
API, Ankleshwar API, Dabhasa Cytotoxic Injectable JV with Pfizer
Topical Formulation Manufacturing,
Pharmez, Ahmedabad
Cytotoxic Injectable Plant,
Pharmez, Ahmedabad
Vaccine Technology Centre, Ahmedabad
APIs & Intermediates mfg JV with Takeda
Finished Dosage Form, Brazil
Liquid and Solid oral dosage products,
Nesher Pharma, USA

OUR
MANUFACTURING
FACILITIES ARE
COMPLIANT WITH
GLOBAL
REGULATORY
STANDARDS
Finished Dosage
Form, Moraiya,
Ahmedabad
M.C.C.
South Africa
ANSM
France
Biologics Active
Substances, Zydus
Biologics,
Ahmedabad
ANVISA
Brazil
PPB
Kenya
FDA
Philippines
MHRA
UK
Transdermals
Manufacturing,
Zydus Technologies
Limited, Pharmez,
Ahmedabad
FDA
US
NDA
Uganda
API, Ahmedabad
NMPB
Sudan
FMHACA
Ethiopia

OUR ACQUISITION TRAIL
GROWING WITH THE TIMES
2017
Made a foray into the specialty prescription
market in the US with the acquisition of
Sentynl Therapeutics Inc., a US based specialty
pharma company.
2007
2011
Acquired 100% stake in Biochem, one of the top
40 pharma companies in India.
Entered into an agreement to acquire the
assets of the US based pharmaceutical
company, Nesher Pharmaceuticals Inc.
Share purchase agreement with Ambalal
Sarabhai Enterprises to acquire the remaining
50% holding in the joint venture company,
Sarabhai Zydus Animal Health Ltd., making it
a 100% subsidiary company of the group.
Acquired Liva Healthcare. This enabled
the group to make a strategic foray in
the Rs 1,500-crore derma market.
Acquired Quimica e Farmaceutica Nikkho do
Brasil Ltda. (Nikkho).
2008
2016
Strategic acquisition of select brands and
the manufacturing operations in
Haridwar, India, of Zoetis
- a global animal health company.
2009
Acquired Laboratorios Combix,
Spain, Simayla Pharmaceuticals
of South Africa and Etna Biotech
of Italy.
2006
Acquired remaining 30% shareholding
of Simayla Pharmaceuticals, South
Africa making it a 100% subsidiary of
the group
Acquired Carnation Nutra-Analogue Foods Ltd,
which manufactures Nutralite – India’s largest
selling premium margarine.
2003
Acquired Alpharma France SAS. This was the
first overseas acquisition of the group.
2001
Acquired German Remedies Ltd.
With this, Zydus gained leadership in
the women’s healthcare, respiratory
and oncology segments.
Acquired Aten. This catapulted
Zydus Cadila to the top spot in
the cardiovascular segment.
2002
Acquired Banyan Chemicals, a
company with a USFDA
approved API plant.
2000
Acquired Recon Healthcare.
This strategic move boosted
the group’s strengths in the
southern markets of India.
1995
Acquired Indo Pharma Pharmaceutical Works Ltd – this was
the very first acquisition by the group. Indo Pharma (later
re-named as Indon) was a 56-year-old company.

ZYDUS – PARTNERING WITH
GLOBAL PHARMA MAJORS
JOINT VENTURES
API manufacturing plant at
Navi Mumbai, Maharashtra, India
Oncology injectibles plant at
Ahmedabad, Gujarat, India
A marketing JV company
headquartered at Mumbai, India
COLLABORATIONS AND ALLIANCES

QUEST - QUALITY EXCELLENCE BY
SUSTAINABLE TRANSFORMATION
Re-emphasising our commitment to quality, we
have launched QUEST - Quality Excellence by
Sustainable Transformation, a programme that
focuses on building a robust quality culture,
creating awareness amongst employees on the
best-practices on the shopoor and simplifying
current practices and procedures. It is a
movement that helps us do the right things, work
together as a team, be the conscious keepers of
each other and ensure that we look at achieving
quality excellence beyond compliance. This
programme which looks at continuous
improvement and institutionalising a quality
culture has been harmonised across all our
manufacturing facilities.
AT A GLANCE...
16
Sites touched
through QUEST
Quality improvement
5000+ ideas implemented
7800+
124+
Employees covered
through QUEST
Circles launched
across all sites
6500+
Frontline employees rewarded
as part of R&R program
Visual dashboards installed
227+ across shop floor
213+
Circle mentors & ICs
trained on QUEST
Culture academy team
23+ members on-boarded
938+
Circle representatives
trained on circle operations
Trainers on-boarded to create
quality-related awareness
325+ amongst frontline employees

TOWARDS OPERATIONAL EXCELLENCE –
THE STORY OF OUR CONTINUOUS IMPROVEMENT
The Operational Excellence (OE) programme,
carved out from the legacy SLIM and PRISM
programmes and the newly set up Manufacturing
Excellence (ME) team is a part of Tech-Ops
organization.
PRISM primarily drives cost excellence across
various verticals and processes by delivering cost
savings in the entire spend base especially
focused on the Direct material and Indirect cost
savings. Ever since revitalization in 2012, the
PRISM program has successfully generated
substantial savings from categories driven along
the 6 waves.
Strategic Lean Integrated Manufacturing (SLIM) is
a top driven (Strategy Deployment) and bottom
up (Kaizen Ideas) approach with a focus on
improving the value in the end-to-end
manufacturing operations. Since the inception of
SLIM, more than 6500 ideas have been
generated by the 25 sites/teams; covering key
operational eciency improvement levers like OEE, cycle
time, changeover time, manpower productivity, yield
improvement, energy conservation etc.
Understanding the pulse of immediate and future
challenges, the Operational excellence program is
fortified with a new initiative i.e. Manufacturing
Excellence. With an objective to create a capable Lean
Sigma organization, the initiative provides a hands on
support to the mfg. sites to deliver projects and
performance improvement.
Over the years, the Operational Excellence programme
has evolved from being just a cost saving or process
improvement programme. and has become an
established part of our work culture that continues to
open new pathways to add value in every step of our
manufacturing process.

BUILDING PEOPLE TO BUILD OUR BUSINESS
Building people capabilities and giving them ample space and freedom to grow and spread their wings has
always been our group’s value proposition for talent both within and outside the organisation.
We build People to Build our Business – was the motto since 1995, as we grew into a multi-locational,
innovation-driven global healthcare company. With over 21,000 people across geographies, our group today is
a conuence of cultures, celebrating diversity.
OUR CORE BEHAVIOURS
The Zydus core behaviours have been created to
support and underpin the purpose of our existence
and the values we abide by. It’s an attempt to
explain and define the expected behaviours from
Zydans across the group and provide a framework
on how we connect, work and carry out our roles
with the organisation. At the heart of it all is the
guiding philosophy of putting the organisation
before self and thinking of Zydus First. The other
interlinked behaviours are keeping pace with change, being
action oriented with a focus on execution excellence, being
innovative in all that we do, focussing on ‘we’ not I,
reinforcing the culture of collaboration, doing the right
things in the right way at the right time to foster trust and
integrity and treating people with respect at all times.
Excellence in
execution
Being
action-oriented
Innovation
Being innovative
in all that we do
Team &
Collaboration
WE not ‘I’
Adaptability
to change
Keeping pace
with change
Putting organisation
before Self
Think Zydus First
Respect,
Trust & Integrity
Doing the right things,
in the right way
at the right time

ZYDUS – COMBINING WORK AND FUN FOR
A PRODUCTIVE ENVIRONMENT
At Zydus, fun and work take on a new meaning
altogether. We have instituted many fun activities
that are organised for Zydans, Zydan Spouses and
Junior Zydans.
Zydans celebrate festivals together, share
moments of joy through interesting contests like
painting, drawing, skill display, talent hunts, cooking
competitions and many more and even organise
interactive workshops for the entire Zydan family.
Recently, we launched the Zydus Clubs, which
encourage Zydans to pursue their passions &
hobbies and connect beyond work.
The Zydus Clubs - Zydus Live Wires, Zydus
Shotguns and Zydus Peace Mill - help connect
Zydans with each other and make them realise
their complete potential as human beings in
addition to being productive members of the
Zydan community.
Community of Aficionado for
Dance, Music and Theatre
Community of
Aficionado for Sports
Community of
Aficionado for Sports

ZYDUS – CREATING A MEANINGFUL
IMPACT IN THE COMMUNITY
Zydus Srishti, the Zydus group’s CSR
programme, is about reaching out to make a
difference in myriad ways in areas of health
Swaasthya’, education Shiksha’ and research
Shodh’. Through these initiatives, the group
reaches out to the community that it forms a
part of, finding new expressions for its mission
of creating healthier communities globally.
Zydus Srishti focuses on the three core areas that
were close to Zydus’ Late Founder Chairman,
Mr. Ramanbhai B. Patel’s heart Healthcare,
Research and Education. The Ramanbhai Foundation,
set up in his memory, continues to keep these
initiatives alive through Zydus Srishti.
Education: Founded a decade ago, Zydus School
for Excellence provides young learners a creative
learning environment.
GCS MEDICAL COLLEGE,
HOSPITAL AND
RESEARCH CENTRE
(GCSMCH)
Inauguration of GCS Medical College, Hospital and
Research Centre in 2011 by the then Chief Minister of Gujarat,
Honble Shri Narendra Modi
Supporting the mission to offer healthcare and
medical services to people from disadvantaged and
underprivileged backgrounds, Supporting the GCS
Medical College, Hospital and Research Centre
(GCSMCH) which was set up at Ahmedabad in 2011
in a uniue public-private partnership model.

The Ramanbhai Foundation supports learning in the
community and at the grassroot level through memorial
lectures and Shreshtha Shikshak Award which honours
teachers in the rural heartland of Gujarat.
Research: A biennial,
global knowledge-sharing
forum is hosted by the
Ramanbhai Foundation to
look at new advances in
new drug discovery at the
Zydus Research Centre. A
panel of eminent scientists
and researchers from abroad share their insights
on new trends and discoveries in research.
To serve the needs of the patients and bring world-class
medical education to the rural interiors of Gujarat, the
Government of Gujarat and the Zydus Group in a Public
Private Partnership (PPP) model is setting up the Zydus
Medical College at ahod.
Health, Safety & Environment :
These are the broad themes under
which rural healthcare camps, health
awareness programmes and relief work
during calamities are undertaken.

Zydus Wellness Ltd., is one of the most prominent players in the
consumer packaged goods industry. Present in niche categories like
sugar substitutes, table spreads and the ultra-competitive facial
cleansing category, Zydus Wellness has been contributing to health
of Indians since 1988.
Sugar Free, the agship brand of Zydus Wellness, is a sugar substitute,
which is the market leader in its category.
®
Everyuth is a prominent brand in the facial cleansing market. Enriched with natural ingredients, it is a major
player in categories such as face wash, facial scrubs, peel offs, face packs etc.
Nutralite is a table spread that is positioned as a ‘healthier and delicious’ alternative to butter.
Because of the key USP of this product, it has gained considerable acceptance with the trendy health
conscious segment in the country.

Cadila Healthcare Limited
Zydus Tower, Satellite Cross Roads,
Ahmedabad - 380 015. India.
Phone : +91-79-268 68 100 (20 Lines)
Fax : +91-79-2686 23 65